Targeting of the Mitochondrial TET1 Protein by Pyrrolo[3,2-b]pyrrole Chelators

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Epigenetic modifications, including DNA hydroxymethylation, are crucial in various diseases, notably cancer.
• The ten-eleven translocation 1 (TET1) protein plays a key role in DNA demethylation and is a target for therapeutic intervention.
• Iron chelators are being explored as inhibitors of TET1, presenting potential anticancer strategies.

Purpose of the Study:

• To synthesize and evaluate novel pyrrolopyrrole derivatives as potential TET1 inhibitors.
• To investigate the anticancer activity and cellular localization of promising compounds.

Main Methods:

• Synthesis of pyrrolo[3,2-b]pyrrole derivatives with hydrazide or hydrazone functionalities.
• Enzyme inhibition assays to determine TET1 inhibitory activity (IC50).
• Microscale thermophoresis and molecular docking for mechanism validation.
• In vitro anticancer assays and mitochondrial localization studies using Pearson's correlation coefficient.

Main Results:

• Pyrrolo[3,2-b]pyrrole derivative 1 demonstrated strong TET1 inhibition with an IC50 of 1.33 μM.
• Derivatives 2-6, featuring substituted 2-hydroxybenzylidene moieties, showed no significant TET1 inhibitory activity.
• Derivative 1 exhibited potent in vitro anticancer activity.
• Derivative 1 was found to localize exclusively in mitochondria (Pearson's correlation coefficient = 0.92).

Conclusions:

• Pyrrolo[3,2-b]pyrrole derivative 1 is a potent TET1 inhibitor with significant anticancer properties.
• The exclusive mitochondrial localization of derivative 1 warrants further investigation for targeted cancer therapy.
• This study highlights the therapeutic potential of targeting TET1 with novel small molecules for oncological disorders.